ClinicalTrials.gg
CompletedNCT01111019Updated Feb 15, 2019Results posted

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

A Phase 2 interventional study of Recombinant human growth hormone (r-hGH) in Hypochondroplasia, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in France. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Mar 2006, registered Apr 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Mucopolysaccharidosis IV with a site in France — 8 open to participants now, 8 under way, 1 of them phase 3. Mucopolysaccharidosis IV · France.

Enrollment
11th of 11
19 · median 135
Started
2006
the only one that year
Phase 2
4 of 19
2 open now
Registered
2nd of 19
by date
Lead sponsor
1 of 19
Merck KGaA, Darmstadt, Germany

Among the 19 studies in Mucopolysaccharidosis IV with a site in France, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 2, and was the 2nd registered.

Mucopolysaccharidosis IV

101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.

Browse Mucopolysaccharidosis IV studies →

Open to participants now

8 of the 19 studies in Mucopolysaccharidosis IV with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mucopolysaccharidosis IV with a site in France, or all of them as a file.
02

Study summary

This study is conducted to describe the efficacy and safety of recombinant human growth hormone (r-hGH) treatment Saizen® on children with hypochondroplasia.

03

Conditions studied

  • Hypochondroplasia

Keywords

  • Hypochondroplasia
  • Skeletal dysplasia
  • Growth
  • Growth Hormone
  • Recombinant-human Growth Hormone
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female children with hypochondroplasia defined by a disproportional short limb height and a X-ray evidence of shortening of the long bones and failure of increase in the interpedicular distance between lumbar vertebrae L1 and L5
  • Result of genetic analysis for mutation of gene FGFR3 already known or ongoing analysis at the beginning of the study
  • Chronological age greater than or equal to 3 years
  • Height for chronological age less than or equal to - 2 SDS
  • Bone age less than or equal to 11 years for girls and 13 years for boys
  • A written at the beginning of the pre-treatment period must be obtained from the parent(s)/legal guardian(s). Children able to understand the trial should personally sign and date the written informed consent

Additional inclusion criteria for each study prolongation:

  • Bone age at Month 36 or Month 60 is compatible with treatment prolongation according to investigator opinion
  • Subject is still under r-hGH treatment with Saizen® at Month 36 or Month 60
  • Height gain greater than or equal to + 1 SDS after the 2 first years of treatment for treatment prolongation at Month 36 and growth velocity greater than or equal to 5 centimeter (cm) per year, with bone age less than 14 years for females or less than 16 years for males for treatment prolongation at Month 60
  • According to investigator opinion, gene mutations of the subjects are not in connection with observed side effects during the 3 or 5 first years of treatment
  • An updated written informed consent must be obtained from the parent(s)/legal guardian(s) before the start of each study prolongation. Children able to understand the trial should personally sign and date the written informed consent

Exclusion criteria

Exclusion Criteria:

  • Turner's Syndrome in girls
  • Active malignant neoplastic disease
  • Severe congenital malformations
  • Proliferative or preproliferative diabetic retinopathy
  • Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion
  • Severe psychomotor retardation
  • Diabetes mellitus or history of significant glucose intolerance as defined by a fasting blood glucose greater than 6.4 millimole per liter (mmol/L)
  • Known renal insufficiency as defined by serum creatinine level 1.0 milligram per deciliter (mg/dL) (88 micromole per liter [mcmol/L])
  • Known hepatic disease as defined by elevated liver enzymes or total (* 2 Normal)
  • Current congestive heart failure, untreated hypertension, serious chronic edema of any cause
  • Chronic infectious disease
  • History of intracranial hypertension with papilledema
  • Previous or ongoing treatment with sex therapy such as estrogens or testosterone
  • Previous or ongoing treatment with any therapy that may directly influence growth, including Growth Hormone (GH), Growth Hormone Releasing Hormone (GHRH) and long duration corticosteroids therapy
  • Known to somatropin or any of the
  • Epiphyseal fusion
  • Participation to any clinical study within the 30 days preceding study entry
  • Pregnant females
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    r-hGH (Saizen®)

    Drug: Recombinant human growth hormone (r-hGH)

Interventions

  • Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.

    Also known as: Saizen®, Somatropin

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3

    Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.

    Time frame: Baseline (Month 0), Year 3

  2. Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 4

    Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.

    Time frame: Year 4

Secondary outcomes

  1. Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects

    Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years. SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.

    Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  2. Change From Baseline in Height of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

    Body proportion was measured in terms of height. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  3. Change From Baseline in Upper Segment (Superior) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

    Body proportion was measured in terms of upper segment for standing and sitting position. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  4. Change From Baseline in Weight of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

    The body weight was measured on a certified and calibrated hospital scale. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  5. Change From Baseline in Body Mass Index (BMI) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

    Body proportion measured as BMI. It was calculated according to the formula BMI = Weight (kilogram)/Height square (meter square). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  6. Change From Baseline in Bone Mineral Density (BMD) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years

    Body composition measured as BMD. It was examined at the lumbar spine (L1-L4) and determined annually by dual-energy X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)

  7. Change From Baseline in Percent Body Fat Mass of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years

    Body composition measured as percentage of body fat mass. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)

  8. Change From Baseline in Lean Body Mass (LBM) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years

    Body composition measured as LBM. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.

    Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)

  9. Growth (Height) Velocity of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

    Growth velocity was calculated in terms of height velocity. It corresponded to a difference in height between current and baseline values divided by the time interval between both evaluations. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  10. Head Circumference Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

    Body proportion was measured in terms of head circumference with a tape measure. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)

  11. Osteocalcin Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

    Osteocalcin as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male), 9.5 (only for male)

  12. C-terminal Telopeptide (CTX) Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

    CTX (Blood) as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

    Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male), 9.5 (only for male)

  13. Number of Subjects With Fibroblast Growth Factor Receptor (FGFR3) Mutation

    Genetic analysis was performed to record FGFR3 gene mutation. Genomic DNA was extracted from lymphocytes of collected blood samples using standard procedures. A set of intronic primers was designed based on the genomic sequence of the human FGFR3 gene and used to amplify exons 2-19. Number of subjects with FGFR3 mutation were reported.

    Time frame: Baseline up to 3 years

  14. Number of Subjects With Adverse Event (AE) and Serious Adverse Event (SAE)

    AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose.

    Time frame: Baseline up to 9.5 years

07

Results

Posted Feb 15, 2019

Participant flow

The study was conducted between March 21, 2006 and January 17, 2017.

Participant flow — Overall Study
Milestoner-hGH (Saizen®)
Started19
Completed16
Not completed3
Withdrew: Withdrew prematurely2
Withdrew: Other1

Outcome measures

PrimaryChange From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3

Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.

Time frame:
Baseline (Month 0), Year 3
Reported as:
Mean · Standard Deviation Score (SDS)
Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3
Standard Deviation Score (SDS)r-hGH (Saizen®)
Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 31.39 ± 0.9
PrimaryHeight-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 4

Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.

Time frame:
Year 4
Reported as:
Mean · Standard Deviation Score (SDS)
Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 4
Standard Deviation Score (SDS)r-hGH (Saizen®)
Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 425.6 ± 3.5
SecondaryHeight-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects

Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years. SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.

Time frame:
Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Median · Standard Deviation Score (SDS)
Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects
Standard Deviation Score (SDS)r-hGH (Saizen®)
Male: Year 1-1.82 (-3.4 to -1.4)
Male: Year 2-1.51 (-3.4 to -1.1)
Male: Year 3-1.30 (-3.7 to -1.0)
Male: Year 4-1.49 (-3.7 to -1.0)
Male: Year 5-1.51 (-3.5 to -1.0)
Male: Year 6-2.88 (-3.8 to -2.0)
Male: Year 7-3.9 (-3.9 to -3.9)
Male: Year 8-3.90 (-3.9 to -3.9)
Male: Year 9-5.0 (-5.0 to -5.0)
Male: Year 9.5-5.6 (-5.6 to -5.6)
Female: Year 1-2.69 (-5.3 to -0.6)
Female: Year 2-2.52 (-5.8 to -0.7)
Female: Year 3-2.61 (-6.0 to -0.6)
Female: Year 4-1.09 (-1.5 to -0.9)
Female: Year 5-1.63 (-1.9 to -1.4)
Female: Year 6-2.51 (-3.4 to -1.6)
Female: Year 7-2.74 (-3.7 to -1.8)
Female: Year 8-2.8 (-2.8 to -2.8)
Female: Year 8.5-3.1 (-3.1 to -3.1)
SecondaryChange From Baseline in Height of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

Body proportion was measured in terms of height. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Mean · Centimeter (cm)
Change From Baseline in Height of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Centimeter (cm)r-hGH (Saizen®)
Male: Year 18.10 ± 1.867
Male: Year 214.59 ± 2.527
Male: Year 320.00 ± 3.398
Male: Year 423.74 ± 4.136
Male: Year 529.06 ± 4.809
Male: Year 631.35 ± 8.556
Male: Year 728.40 ± NA
Male: Year 834.73 ± NA
Male: Year 937.98 ± NA
Male: Year 9.538.37 ± NA
Female: Year 17.72 ± 1.642
Female: Year 213.76 ± 3.505
Female: Year 317.95 ± 5.189
Female: Year 426.96 ± 2.394
Female: Year 530.08 ± 3.791
Female: Year 632.50 ± 0.566
Female: Year 736.92 ± 0.024
Female: Year 839.47 ± NA
Female: Year 8.540.87 ± NA
SecondaryChange From Baseline in Upper Segment (Superior) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

Body proportion was measured in terms of upper segment for standing and sitting position. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Mean · Centimeter (cm)
Change From Baseline in Upper Segment (Superior) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Centimeter (cm)r-hGH (Saizen®)
Male: Year 13.80 ± 1.656
Male: Year 27.96 ± 4.172
Male: Year 38.93 ± 9.504
Male: Year 416.50 ± NA
Male: Year 516.98 ± 2.161
Male: Year 617.05 ± 6.576
Male: Year 918.70 ± NA
Male: Year 9.527.80 ± NA
Female: Year 14.19 ± 0.909
Female: Year 29.21 ± 2.450
Female: Year 313.41 ± 1.978
Female: Year 415.70 ± 2.546
Female: Year 515.20 ± 0.849
Female: Year 618.35 ± 0.354
Female: Year 721.90 ± 0.707
Female: Year 824.40 ± NA
SecondaryChange From Baseline in Weight of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

The body weight was measured on a certified and calibrated hospital scale. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Mean · Kilogram (kg)
Change From Baseline in Weight of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Kilogram (kg)r-hGH (Saizen®)
Male: Year 14.58 ± 2.715
Male: Year 29.95 ± 4.577
Male: Year 315.18 ± 6.259
Male: Year 414.25 ± 3.948
Male: Year 520.00 ± 7.024
Male: Year 625.00 ± 11.314
Male: Year 719.00 ± NA
Male: Year 823.00 ± NA
Male: Year 928.90 ± NA
Male: Year 9.531.00 ± NA
Female: Year 14.72 ± 1.537
Female: Year 29.85 ± 3.946
Female: Year 314.37 ± 4.905
Female: Year 414.70 ± 5.510
Female: Year 514.93 ± 3.101
Female: Year 621.25 ± 1.061
Female: Year 726.25 ± 1.061
Female: Year 835.20 ± NA
Female: Year 8.538.00 ± NA
SecondaryChange From Baseline in Body Mass Index (BMI) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years

Body proportion measured as BMI. It was calculated according to the formula BMI = Weight (kilogram)/Height square (meter square). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Mean · Kilogram per meter square (kg/m^2)
Change From Baseline in Body Mass Index (BMI) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Kilogram per meter square (kg/m^2)r-hGH (Saizen®)
Male: Year 10.43 ± 0.579
Male: Year 21.56 ± 0.968
Male: Year 32.71 ± 1.302
Male: Year 42.21 ± 1.147
Male: Year 53.60 ± 2.240
Male: Year 65.02 ± 1.039
Male: Year 74.43 ± NA
Male: Year 84.57 ± NA
Male: Year 96.63 ± NA
Male: Year 9.57.60 ± NA
Female: Year 10.85 ± 1.112
Female: Year 22.12 ± 1.978
Female: Year 33.49 ± 2.341
Female: Year 42.12 ± 1.778
Female: Year 52.36 ± 2.207
Female: Year 64.90 ± 0.634
Female: Year 76.19 ± 0.408
Female: Year 89.83 ± NA
Female: Year 8.510.71 ± NA
SecondaryChange From Baseline in Bone Mineral Density (BMD) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years

Body composition measured as BMD. It was examined at the lumbar spine (L1-L4) and determined annually by dual-energy X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)
Reported as:
Mean · Gram per square centimeter (g/cm^2)
Change From Baseline in Bone Mineral Density (BMD) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years
Gram per square centimeter (g/cm^2)r-hGH (Saizen®)
Male: Year 10.05 ± 0.050
Male: Year 20.11 ± 0.063
Male: Year 30.14 ± 0.059
Male: Year 40.11 ± 0.054
Male: Year 50.15 ± 0.064
Male: Year 60.18 ± 0.182
Male: Year 80.06 ± NA
Male: Year 90.12 ± NA
Female: Year 10.05 ± 0.042
Female: Year 20.09 ± 0.053
Female: Year 30.15 ± 0.089
Female: Year 40.22 ± 0.104
Female: Year 50.17 ± 0.006
Female: Year 60.19 ± 0.004
Female: Year 70.26 ± 0.028
Female: Year 80.40 ± NA
SecondaryChange From Baseline in Percent Body Fat Mass of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years

Body composition measured as percentage of body fat mass. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)
Reported as:
Mean · Percentage (%) of body fat mass
Change From Baseline in Percent Body Fat Mass of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years
Percentage (%) of body fat massr-hGH (Saizen®)
Male: Year 1-4.54 ± 2.049
Male: Year 2-4.49 ± 3.007
Male: Year 3-2.80 ± 3.967
Male: Year 4-3.40 ± 4.493
Male: Year 5-2.33 ± 5.708
Male: Year 6-0.65 ± 11.384
Male: Year 85.70 ± NA
Male: Year 91.90 ± NA
Female: Year 1-3.50 ± 3.185
Female: Year 2-2.27 ± 4.441
Female: Year 3-2.74 ± 5.227
Female: Year 4-1.40 ± 3.536
Female: Year 5-2.50 ± 1.131
Female: Year 60.05 ± 6.576
Female: Year 7-0.50 ± 5.798
SecondaryChange From Baseline in Lean Body Mass (LBM) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years

Body composition measured as LBM. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.

Time frame:
Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)
Reported as:
Mean · Gram (g)
Change From Baseline in Lean Body Mass (LBM) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years
Gram (g)r-hGH (Saizen®)
Male: Year 14966.46 ± 2670.694
Male: Year 29134.35 ± 4747.742
Male: Year 311182.24 ± 4126.876
Male: Year 411599.80 ± 4560.877
Male: Year 515729.38 ± 6102.608
Male: Year 620667.65 ± 14985.50
Male: Year 815773.80 ± NA
Male: Year 921713.10 ± NA
Female: Year 14384.54 ± 1400.497
Female: Year 26720.74 ± 2597.295
Female: Year 39229.21 ± 2740.883
Female: Year 411791.85 ± 1173.161
Female: Year 512989.50 ± 83.439
Female: Year 614860.75 ± 2140.483
Female: Year 718111.60 ± 1239.275
SecondaryGrowth (Height) Velocity of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

Growth velocity was calculated in terms of height velocity. It corresponded to a difference in height between current and baseline values divided by the time interval between both evaluations. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Mean · Centimeter per year (cm/year)
Growth (Height) Velocity of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
Centimeter per year (cm/year)r-hGH (Saizen®)
Male: Year 18.21 ± 2.001
Male: Year 27.26 ± 1.292
Male: Year 36.55 ± 1.104
Male: Year 45.88 ± 1.060
Male: Year 55.77 ± 0.968
Male: Year 64.98 ± 1.313
Male: Year 73.92 ± NA
Male: Year 84.25 ± NA
Male: Year 94.11 ± NA
Male: Year 9.53.94 ± NA
Female: Year 17.53 ± 1.460
Female: Year 26.64 ± 1.713
Female: Year 35.86 ± 1.677
Female: Year 46.57 ± 0.572
Female: Year 55.89 ± 0.787
Female: Year 65.13 ± 0.006
Female: Year 75.06 ± 0.120
Female: Year 84.69 ± NA
Female: Year 8.54.54 ± NA
SecondaryHead Circumference Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

Body proportion was measured in terms of head circumference with a tape measure. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Reported as:
Mean · Centimeter (cm)
Head Circumference Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
Centimeter (cm)r-hGH (Saizen®)
Male: Year 156.11 ± 1.268
Male: Year 256.53 ± 1.359
Male: Year 357.38 ± 1.734
Male: Year 457.33 ± 2.021
Male: Year 556.88 ± 1.887
Male: Year 655.50 ± NA
Male: Year 757.00 ± NA
Male: Year 957.50 ± NA
Male: Year 9.558.00 ± NA
Female: Year 155.20 ± 2.379
Female: Year 256.06 ± 1.841
Female: Year 356.23 ± 2.453
Female: Year 458.00 ± NA
Female: Year 554.33 ± 3.512
Female: Year 657.25 ± 1.768
Female: Year 756.75 ± 1.061
Female: Year 859.00 ± NA
SecondaryOsteocalcin Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

Osteocalcin as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male), 9.5 (only for male)
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Osteocalcin Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
Nanogram per milliliter (ng/mL)r-hGH (Saizen®)
Male: Year 1123.06 ± 55.820
Male: Year 2145.00 ± 35.705
Male: Year 3130.13 ± 36.408
Male: Year 4101.00 ± 34.708
Male: Year 5139.25 ± 76.908
Male: Year 675.50 ± 47.376
Male: Year 7113.00 ± NA
Male: Year 8117.00 ± NA
Male: Year 9159.80 ± NA
Male: Year 9.5131.60 ± NA
Female: Year 1148.00 ± 46.183
Female: Year 2122.82 ± 46.531
Female: Year 394.73 ± 33.344
Female: Year 4102.00 ± 26.268
Female: Year 584.33 ± 22.591
Female: Year 6106.00 ± 22.627
Female: Year 777.50 ± 19.092
Female: Year 873.70 ± NA
SecondaryC-terminal Telopeptide (CTX) Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years

CTX (Blood) as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.

Time frame:
Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male), 9.5 (only for male)
Reported as:
Mean · picomole per liter (pmol/L)
C-terminal Telopeptide (CTX) Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
picomole per liter (pmol/L)r-hGH (Saizen®)
Male: Year 115784.17 ± 1426.214
Male: Year 216304.13 ± 2537.725
Male: Year 315703.50 ± 3249.336
Male: Year 415868.25 ± 4485.621
Male: Year 517088.75 ± 5208.676
Male: Year 612361.00 ± 4000.810
Male: Year 713795.00 ± NA
Male: Year 815345.00 ± NA
Male: Year 915655.00 ± NA
Male: Year 9.517205.00 ± NA
Female: Year 116008.00 ± 2725.874
Female: Year 215183.09 ± 4371.058
Female: Year 312595.18 ± 3172.529
Female: Year 413911.00 ± 1076.509
Female: Year 512503.33 ± 2867.849
Female: Year 613678.50 ± 603.162
Female: Year 713446.50 ± 931.260
Female: Year 811858.00 ± NA
SecondaryNumber of Subjects With Fibroblast Growth Factor Receptor (FGFR3) Mutation

Genetic analysis was performed to record FGFR3 gene mutation. Genomic DNA was extracted from lymphocytes of collected blood samples using standard procedures. A set of intronic primers was designed based on the genomic sequence of the human FGFR3 gene and used to amplify exons 2-19. Number of subjects with FGFR3 mutation were reported.

Time frame:
Baseline up to 3 years
Reported as:
Number · Subjects
Number of Subjects With Fibroblast Growth Factor Receptor (FGFR3) Mutation
Subjectsr-hGH (Saizen®)
Number of Subjects With Fibroblast Growth Factor Receptor (FGFR3) Mutation14
SecondaryNumber of Subjects With Adverse Event (AE) and Serious Adverse Event (SAE)

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose.

Time frame:
Baseline up to 9.5 years
Reported as:
Number · Subjects
Number of Subjects With Adverse Event (AE) and Serious Adverse Event (SAE)
Subjectsr-hGH (Saizen®)
AEs18
SAEs1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
r-hGH (Saizen®)0/19 (0%)1/19 (5.3%)18/19 (94.7%)
Most frequent serious events
Most frequent serious events
Eventr-hGH (Saizen®)
Abdominal painGastrointestinal disorders1/19
AppendicitisInfections and infestations1/19
Most frequent other events
Showing 10 of 67
Most frequent other events
Eventr-hGH (Saizen®)
ArthralgiaMusculoskeletal and connective tissue disorders7/19
Abdominal PainGastrointestinal disorders5/19
ScoliosisMusculoskeletal and connective tissue disorders5/19
Knee deformityMusculoskeletal and connective tissue disorders4/19
HeadacheNervous system disorders4/19
PyrexiaGeneral disorders3/19
BronchitisInfections and infestations3/19
GastroenteritisInfections and infestations3/19
Insulin-like growth factor increasedInvestigations3/19
Vitamin D deficiencyMetabolism and nutrition disorders3/19

Baseline characteristics

Intention to Treat (ITT) population included all subjects who received at least one dose of treatment with at least an efficacy assessment available during the treatment period.

Age, Continuous
Age, Continuous(Years)r-hGH (Saizen®)
Mean9.0 ± 3.12
Sex/Gender, Customized
Sex/Gender, Customized(Participants)r-hGH (Saizen®)
Female11
Male8
08

Study locations

1 site
  • Endocrinologie Pédiatrique - centre des maladies rares de la croissance -Hôpital Necker Enfants Malades
    Paris, 75015, France
09

References and documents

Publications

  • Pinto G, Cormier-Daire V, Le Merrer M, Samara-Boustani D, Baujat G, Fresneau L, Viaud M, Souberbielle JC, Pineau JC, Polak M. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort. Horm Res Paediatr. 2014;82(6):355-63. doi: 10.1159/000364807. Epub 2014 Oct 15. PubMed 25323764 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2006 to primary completion in Jan 2017, 129 months.

Results were first posted in Feb 2019, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2010
First posted
Apr 27, 2010
StartActual
Mar 21, 2006
Primary completionActual
Jan 17, 2017
CompletionActual
Jan 17, 2017
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01111019
Collaborators
Merck Serono S.A.S, France
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
Mar 21, 2006
Primary completion
Jan 17, 2017
Completion
Jan 17, 2017
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion